15 septiembre 2015
BRD4 inhibitors are among the most promising new agents in cancer therapy that are currently evaluated in clinical trials. In a new study, a team of researchers reveals how leukemia cells can evade the deadly effects of BRD4 inhibition. Understanding this adaptation process could aid the development of sequential therapies to outsmart resistant leukemias.
http://www.sciencedaily.com/releases/2015/09/150915090657.htm
